# FID-022

Source: https://onco.cc/drugs/fid-022/  
OnCo record `fid-022` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FID-022 is an experimental nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy from Fulgent Genetics, in phase 1 trials for advanced solid tumours.

## Summary

FID-022 is a nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material) from Fulgent Genetics. SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06694480 recruiting; dose levels 1-4 completed (July 2026 deck). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: FID-022
- Modality: Nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material)
- Mechanism: SN38 and its prodrug irinotecan encapsulated in a polyethyloxazoline (PEOX) material.

## Sources

- Fulgent Genetics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06694480
- Fulgent Genetics: sec.gov: https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm
- ClinicalTrials.gov: trials of FID-022: https://clinicaltrials.gov/search?intr=FID-022

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Fulgent Genetics](https://onco.cc/companies/fulgent-genetics/)
- trials: [Study of FID-022 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06694480/)

---
JSON: https://onco.cc/api/v1/entities/fid-022.json